Type II calcimimetics and polycystic kidney disease: unanswered questions.
Torres
Vicente E
VE
D000814:Aniline Compounds / Q000627:therapeutic use*; D000818:Animals; D002118:Calcium / Q000819:agonists*; D002125:Calcium Gluconate / Q000627:therapeutic use*; D004195:Disease Models, Animal; D018450:Disease Progression; D008297:Male; D010627:Phenethylamines; D007690:Polycystic Kidney Diseases / Q000517:prevention & control*; D011437:Propylamines; D051381:Rats
D000814:Aniline Compounds; C107873:N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine; D010627:Phenethylamines; D011437:Propylamines; D002125:Calcium Gluconate; D002118:Calcium